The findings regarding the diverse effects of cilostazol on PCSK9 expression between obese and non-obese conditions (in vitro, in vivo, or clinically) are novel, suggesting another mechanisms of action are responsible for the anti-atherosclerotic effects of cilostazol for obesity. This evidence concerns the gene PCSK9 and obesity due to melanocortin 4 receptor deficiency.